Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Colquhoun, David Martin
ASPIRE-AF, NCT03968393 / 2019-001336-62: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery	Recruiting	4	2270	Europe, Canada, RoW	Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban	Population Health Research Institute, Hamilton Health Sciences Corporation	Stroke, Atrial Fibrillation	12/26	12/28
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Active, not recruiting	3	1500	Europe, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Type 2 Diabetes	08/25	08/25
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease	Active, not recruiting	3	1800	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Cardiovascular Diseases	01/26	02/26
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Active, not recruiting	3	405	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteo Arthritis Knee	02/26	03/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight	Active, not recruiting	3	1000	Europe, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea	05/26	05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
NCT06700720: YN001-004 in Patients With Coronary Atherosclerosis in Australia	Not yet recruiting	2	12	RoW	Dose 1 YN001, Dose 2 YN001, Evolocumab, Repatha®	Beijing Inno Medicine Co., Ltd.	Coronary Artery Disease, Coronary Atherosclerotic Disease	09/25	09/25
NCT05420077: Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273	Terminated	1	13	RoW	RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg	RVAC Medicines (US), Inc.	Infectious Disease, COVID-19	06/23	06/23
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Active, not recruiting	1	16	Europe, Japan, US, RoW	Mezagitamab, TAK-079	Takeda	Kidney Disease, Glomerulonephritis	03/26	03/26